Beta-blockade enhances anthracycline control of metastasis in triple-negative breast cancer
Science Translational Medicine · 26.04.2023 · 15 (693)
DOI: 10.1126/scitranslmed.adf1147 ↗Kurz gefasst
Fachartikel in der Zeitschrift Science Translational Medicine, erschienen am 26.04.2023. Verfasst von Aeson Chang und 24 weiteren Autor:innen. Beteiligte Einrichtung: Drug Discovery Biology Theme, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, VIC 3052, Australia. Hauptthemen laut MEDLINE: Anthracyclines, Triple Negative Breast Neoplasms. Die Arbeit wurde bisher 103-mal zitiert (Crossref) und nennt 49 Literaturangaben.
Abstract (Originalsprache)
Beta-adrenergic blockade has been associated with improved cancer survival in patients with triple-negative breast cancer (TNBC), but the mechanisms of these effects remain unclear. In clinical epidemiological analyses, we identified a relationship between beta-blocker use and anthracycline chemotherapy in protecting against TNBC progression, disease recurrence, and mortality. We recapitulated the effect of beta-blockade on anthracycline efficacy in xenograft mouse models of TNBC. In metastatic 4T1.2 and MDA-MB-231 mouse models of TNBC, beta-blockade improved the efficacy of the anthracycline doxorubicin by reducing metastatic development. We found that anthracycline chemotherapy alone, in the absence of beta-blockade, increased sympathetic nerve fiber activity and norepinephrine concentration in mammary tumors through the induction of nerve growth factor (NGF) by tumor cells. Moreover, using preclinical models and clinical samples, we found that anthracycline chemotherapy up-regulated β 2 -adrenoceptor expression and amplified receptor signaling in tumor cells. Neurotoxin inhibition of sympathetic neural signaling in mammary tumors using 6-hydroxydopamine or genetic deletion of NGF or β 2 -adrenoceptor in tumor cells enhanced the therapeutic effect of anthracycline chemotherapy by reducing metastasis in xenograft mouse models. These findings reveal a neuromodulatory effect of anthracycline chemotherapy that undermines its potential therapeutic impact, which can be overcome by inhibiting β 2 -adrenergic signaling in the tumor microenvironment. Supplementing anthracycline chemotherapy with adjunctive β 2 -adrenergic antagonists represents a potential therapeutic strategy for enhancing the clinical management of TNBC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Drug Discovery Biology Theme, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, VIC 3052, Australia.
- Department of Research, Cancer Registry of Norway, Oslo 0379, Norway.
- Jreissati Pancreatic Centre, Epworth HealthCare, Richmond, VIC 3121, Australia.
- Drug Delivery, Disposition, and Dynamics Theme, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, VIC 3052, Australia.
- Insitro, San Francisco, CA 94080, USA.
- Department of Breast Surgery, International University of Health and Welfare, Narita, Chiba 286-8520, Japan.
ORCID-Profile: Aeson Chang, Edoardo Botteri, Lukas Löfling, Alexandra I Ziegler, Ni-Chun Chung, Stewart A Fabb, Cameron J Nowell, Sasagu Kurozumi, Sara Gandini, Elisabetta Munzone, Ayaka Katayama, Tetsunari Oyama, Steve W Cole, Gavin W Lambert, Adam K Walker, Erica K Sloan
Zitieren
APA
Chang, A., Botteri, E., Gillis, R. D., Löfling, L., Le, C. P., Ziegler, A. I., Chung, N. C., Rowe, M. C., Fabb, S. A., Hartley, B. J., Nowell, C. J., Kurozumi, S., Gandini, S., Munzone, E., Montagna, E., Eikelis, N., Phillips, S. E., Honda, C., Masuda, K., …, & Sloan, E. K. (2023). Beta-blockade enhances anthracycline control of metastasis in triple-negative breast cancer. Science Translational Medicine, 15(693). https://doi.org/10.1126/scitranslmed.adf1147
Vancouver
Chang A, Botteri E, Gillis RD, Löfling L, Le CP, Ziegler AI, et al. Beta-blockade enhances anthracycline control of metastasis in triple-negative breast cancer. Science Translational Medicine. 2023;15(693). doi:10.1126/scitranslmed.adf1147
BibTeX
@article{Chang2023,
author = {Chang, Aeson and Botteri, Edoardo and Gillis, Ryan D and Löfling, Lukas and Le, Caroline P and Ziegler, Alexandra I and Chung, Ni-Chun and Rowe, Matthew C and Fabb, Stewart A and Hartley, Brigham J and Nowell, Cameron J and Kurozumi, Sasagu and Gandini, Sara and Munzone, Elisabetta and Montagna, Emilia and Eikelis, Nina and Phillips, Sarah E and Honda, Chikako and Masuda, Kei and Katayama, Ayaka and Oyama, Tetsunari and Cole, Steve W and Lambert, Gavin W and Walker, Adam K and Sloan, Erica K},
title = {Beta-blockade enhances anthracycline control of metastasis in triple-negative breast cancer},
journal = {Science Translational Medicine},
year = {2023},
volume = {15},
number = {693},
doi = {10.1126/scitranslmed.adf1147}
}
EUVIMED